Key Highlights
- Shares retreated after reaching a fresh 52-week peak of $10.93, with the decline attributed to a technical pullback from elevated levels
- First-quarter fiscal 2027 results scheduled for pre-market release on June 25, with Street forecasts calling for $0.03 earnings per share and $137.7 million in sales
- Previous quarter delivered an earnings surprise with $0.06 per share versus $0.04 anticipated, alongside revenue of $157.96 million representing 10.1% annual growth
- Wall Street maintains a Hold rating with an average target of $5.73; CIBC upgraded shares to Outperform with a $10.00 objective
- Company executives offloaded shares in early April at $3.56; total insider dispositions reached 73,171 shares valued at approximately $260,000 over three months
BlackBerry (BB) shares commenced trading Thursday at $8.84, sliding roughly 3.6% as investors booked gains following an aggressive advance that propelled the security to a 52-week summit of $10.93. The equity has soared 133% since the beginning of the year.
The decline doesn’t seem connected to any unfavorable corporate developments. Market observers attribute the move to a classic technical retracement following a powerful rally that elevated BB into overbought conditions.
Attention is now shifting to the upcoming financial disclosure. BlackBerry plans to unveil first-quarter fiscal 2027 figures prior to Thursday’s opening bell on June 25. The conference call is slated for 8:00 AM Eastern Time.
Street projections call for earnings of $0.03 per share on top-line results of $137.65 million for the period. This would represent a decline from the previous quarter’s impressive performance.
BlackBerry’s latest quarterly report, released on April 9, significantly exceeded analyst projections. The firm delivered $0.06 per share compared to the $0.04 Street estimate and generated $157.96 million in revenue versus forecasts of $144.27 million — marking a 10.1% increase from the prior-year period.
For the complete fiscal year 2027, executives have established earnings guidance ranging from $0.15 to $0.19 per share. First-quarter projections stand between $0.02 and $0.03 per share.
Wall Street Price Objectives Show Wide Dispersion
The research community remains split on BB. Canadian Imperial Bank of Commerce distinguishes itself, elevating its price objective from $8.50 to $10.00 recently while assigning an Outperform designation.
This stance proves considerably more bullish than competing views. Canaccord Genuity trimmed its target from $4.60 to $4.40 in April while maintaining a Hold recommendation. Royal Bank of Canada sustained a Sector Perform rating with a $4.50 objective. Weiss Ratings downgraded the security modestly to a Hold (C-) on June 4.
The Street consensus suggests a Hold rating with a mean price target of $5.73 — substantially beneath the stock’s current valuation.
Executive Stock Dispositions Occurred in April
Chief Executive John Giamatteo disposed of 27,066 shares on April 2 at $3.56 apiece, trimming his holdings by 2.92%. Senior Vice President Jennifer Armstrong-Owen sold 29,908 shares on April 4 at an identical price, reducing her stake by 23.96%.
Total executive sales during the trailing 90-day period amount to 73,171 shares with an aggregate value near $260,000. Company insiders currently control merely 0.51% of outstanding shares.
Regarding institutional activity, Creative Planning expanded its holdings by 87.5% during the second quarter, while multiple funds including Scientech Research and Man Group established fresh positions.
The security’s 50-day moving average rests at $6.76 with its 200-day average positioned at $4.77 — both considerably beneath the present price level, highlighting the velocity of BB’s year-to-date appreciation.
BB maintains a price-to-earnings multiple of 110.50, a beta coefficient of 2.29, and a debt-to-equity ratio of 0.26. The trailing 12-month low registered at $3.12.
The upcoming critical event remains the June 25 quarterly report, where management’s first-quarter guidance of $0.02–$0.03 per share will face validation against reported outcomes.





